- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06452498
자간전증 중재 네덜란드 (PI-NL)
조기 자간전증의 임신 연장을 위한 메트포르민
The goal of this study is to find out if pregnant individuals with preterm preeclampsia (PE) who are treated with metformin can stay pregnant for longer, and if this is safe(r) for the mother and child. Preterm PE affects about 1 in 100 pregnant individuals in the Netherlands. Signs of preterm PE can be high blood pressure and protein in the urine in the second half of pregnancy (but before 32-34 weeks of pregnancy). Other symptoms can develop, such as problems with blood clotting and how well the blood cells, liver, lungs, and brain work. The disease can lead to serious complications for both the mother and child. The only way to cure preterm PE is to make sure the child is born, and many times, children have to be delivered (very) early (before 37 weeks). Children born (very) early can suffer from infections, breathing difficulties, and problems in their development.
Metformin is a medicine used to treat high blood sugar during and outside of pregnancy. In a previous study in South Africa, women with preterm PE that used metformin were able to safely remain pregnant for an extra week. Similarly, the main goal of the Preeclampsia Intervention NetherLands (PI-NL) study is to see if patients with preterm PE in the Netherlands that use metformin can remain pregnant for a longer time than patients taking a placebo. A placebo is a look-a-like capsule that contains no active ingredients. Researchers, the treating medical team, and participants will not know which participant gets which treatment. In addition, all participants will receive the standard care that all preterm PE patients get.
연구 개요
상태
정황
상세 설명
Preterm preeclampsia (PE) is a severe hypertensive disorder of pregnancy and a major cause of maternal and perinatal morbidity and mortality. Currently, the only treatment to halt disease progression is delivery of the dysfunctional placenta and thereby the child. This often happens prematurely. Being able to safely (for mother and child) extend pregnancy, even by a few days, is expected to reduce the short- and long-term risks associated with (severe) prematurity. Preclinical and recent clinical evidence presents metformin, a drug commonly used to treat diabetes in and outside of pregnancy, as a promising treatment candidate for preterm PE. Metformin might reduce inflammation, oxidative stress, and anti-angiogenesis, and improve endothelial function. In a recent South African trial, use of metformin was associated with a safe median 7.6 day prolongation of pregnancy in women with preterm PE, compared to placebo. There was a nonsignificant increase in the neonatal birthweight and a decrease in the length of stay in any neonatal nursery. Metformin did not lead to any serious adverse events.
The goal of this multicenter, triple-blind, randomized placebo-controlled trial is to investigate whether metformin can safely prolong gestation in patients with preterm PE in the Dutch population. Secondary outcomes include composite adverse maternal, fetal, and neonatal outcomes. Cost-effectiveness of the treatment will be evaluated.
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: M. Khelil, MD
- 전화번호: +31 20 566 9111
- 이메일: PI_NL@amsterdamumc.nl
연구 연락처 백업
- 이름: R.C. Painter, Prof, MD, PhD
- 전화번호: +31 20 566 9111
- 이메일: PI_NL@amsterdamumc.nl
연구 장소
-
-
-
Amsterdam, 네덜란드
- 모병
- Amsterdam UMC
-
연락하다:
- Wessel Ganzevoort
- 전화번호: +31205669111
- 이메일: PI_NL@amsterdamumc.nl
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria
All of the following:
- Aged 18 years or older
- Singleton pregnancy
- Gestational age between 23+0 and 31+6 weeks
- A diagnosis of preterm preeclampsia, defined according to modified International Society for the Study of Hypertension in Pregnancy (ISSHP) classification, including only those who have proteinuria (≥300 mg of protein in a 24-hour urine specimen or a protein-creatinine-ratio >50 in a single urine sample)
- Estimated fetal weight >400 grams
- No clear indication (maternal or fetal) or intention, by both the treating multidisciplinary team and the patient after counseling, to immediately deliver (or directly after corticosteroid administration) or to terminate the pregnancy otherwise.
- Ability to understand English or Dutch
- Ability and willingness to provide written informed consent
Exclusion Criteria
Any of the following:
- Current use of metformin or a clinical indication for the use of metformin
- A decision for immediate delivery (including cases where corticosteroids are administered with planned delivery directly after completion of treatment) or termination of pregnancy (e.g., due to disease severity in the patient combined with a dismal prognosis for the fetus), as made by the treating multidisciplinary team and the parent(s)
- Contraindication(s) for the use of metformin (e.g., severe renal insufficiency, acute metabolic acidosis, severe liver insufficiency)
- Use of drugs that might interact with metformin
- Suspicion of a major fetal anomaly and/or chromosomal abnormality
- Unable or unwilling to (completely) understand or provide informed consent, due to language, culture, or other barriers
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Metformin
Metformin 3000 mg divided by three daily doses (3 times 2 capsules of 500 mg; following a step-up schedule) from randomization till delivery, aside from usual preterm preeclampsia care. |
Metformin Hydrochloride encapsulated immediate-release tablet of 500 mg, backfilled with cellulose.
다른 이름들:
|
|
위약 비교기: Placebo
Placebo, divided by three daily doses (3 times 2 capsules; following a step-up schedule) from randomization till delivery, aside from usual preterm preeclampsia care. |
Capsule filled with cellulose. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of days between randomization and delivery
기간: Time between randomization and delivery (up to 37 weeks of gestation)
|
Prolongation of gestation |
Time between randomization and delivery (up to 37 weeks of gestation)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of participants reaching a composite maternal adverse outcome
기간: Randomization till 90 days postpartum (unless otherwise specified)
|
Combined endpoint of maternal death (during pregnancy or within 42 days postpartum), eclampsia, pulmonary edema, severe renal impairment, cerebrovascular accident, placental abruption, and/or liver hematoma or rupture. |
Randomization till 90 days postpartum (unless otherwise specified)
|
|
Number of participants reaching a composite fetal adverse outcome
기간: Randomization till delivery (up to 37 weeks of gestation)
|
Combined endpoint of intrauterine fetal demise, suboptimal fetal condition based on CTG, and fetal growth restriction. |
Randomization till delivery (up to 37 weeks of gestation)
|
|
Number of participants reaching a composite neonatal adverse outcome
기간: Birth till 90 days after birth (unless otherwise specified)
|
Combined endpoint of neonatal death (within 28 days after birth), grade 3 or 4 intraventricular hemorrhage, retinopathy of prematurity requiring treatment, necrotizing enterocolitis (grade II or higher), bronchopulmonary dysplasia, neonatal sepsis, and cystic periventricular leukomalacia (grade II or higher) |
Birth till 90 days after birth (unless otherwise specified)
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Maternal individual exploratory outcomes
기간: Randomization till 90 days postpartum (unless otherwise specified)
|
Number of participants experiencing each of the following: maternal death, cerebrovascular event, eclampsia, cortical blindness, pulmonary edema, AKI, liver hematoma/rupture, placental abruption, retinal detachment, postpartum hemorrhage, HELLP syndrome, severe elevated liver enzymes, low platelets, left ventricular heart failure, PRES, DIC, thromboembolic disease, need for dialysis due to renal failure, admission to high or ICU, need for intubation and mechanical ventilation |
Randomization till 90 days postpartum (unless otherwise specified)
|
|
Fetal individual exploratory outcomes
기간: Randomization till 90 days postpartum (unless otherwise specified)
|
Number of participants experiencing each of the following: intrauterine or intrapartum fetal death, reversed end diastolic flow in umbilical artery on at least 2 occasions, redistribution in the middle cerebral artery, absent or reversed a-wave in ductus venosus, suboptimal fetal condition based on CTG. |
Randomization till 90 days postpartum (unless otherwise specified)
|
|
Neonatal individual exploratory outcomes
기간: Randomization till 90 days postpartum (unless otherwise specified)
|
Number of participants experiencing each of the following: neonatal death within 28 days after birth, neonatal death between 29 and 90 days after birth, growth restriction at birth, Apgar score < 7 at 5 min, umbilical artery pH < 7.10, neonatal hypoglycemia, neonatal seizures, intraventricular hemorrhage, necrotizing enterocolitis, retinopathy of the premature, pulmonary insufficiency of the preterm infant, bronchopulmonary dysplasia, cystic periventricular leukomalacia, patent ductus arteriosus, persistent pulmonary hypertension, surfactant use within 72 hours after birth, need for respiratory support, admission to NICU. |
Randomization till 90 days postpartum (unless otherwise specified)
|
|
Mean neonatal birthweight
기간: Within the first 24 hours after birth
|
In grams |
Within the first 24 hours after birth
|
|
Median neonatal length of stay in any neonatal nursery, including NICU
기간: Birth till 90 days postpartum
|
In days |
Birth till 90 days postpartum
|
|
Incremental cost-effectiveness ratios (ICERs; exploratory)
기간: Start of pregnancy till 90 days postpartum
|
Determined through length of maternal stay in hospital (and specifically ICU), neonatal length of stay in hospital (and specifically NICU), other health care utilization (based on iMCQ questionnaire, maternal and neonatal use of medication during pregnancy and after birth), loss of productivity (measured with iPCQ questionnaire), quality-of-life (score on EQ-5D-5L). |
Start of pregnancy till 90 days postpartum
|
|
Rate of diarrhea, nausea/vomiting, abdominal pain, headache (all based on PHASE-20 questionnaire), lactic acidosis, and hypoglycemia (individually)
기간: Randomization till delivery (up to 37 weeks of gestation)
|
Tolerability and safety of metformin |
Randomization till delivery (up to 37 weeks of gestation)
|
|
Score on PROMIS Anxiety 8a Short Form
기간: Randomization till 90 days postpartum
|
Maternal anxiety |
Randomization till 90 days postpartum
|
|
Score on EPDS
기간: Randomization till 90 days postpartum
|
Maternal depressive symptoms |
Randomization till 90 days postpartum
|
|
Score on Rosenberg Self-Esteem Scale
기간: Randomization till 90 days postpartum
|
Maternal self-esteem |
Randomization till 90 days postpartum
|
|
Score on City Birth Trauma Scale
기간: Randomization till 90 days postpartum
|
Childbirth-related PTSD |
Randomization till 90 days postpartum
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: R.C. Painter, Prof, MD, PhD, Amsterdam UMC
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- PI-NL trial
- 2023-510382-10-00 (씨티스)
- 2023 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The investigators plan to collaborate with researchers of the international Preeclampsia Intervention (PI) trials.
IPD 공유 기간
T.b.d.
IPD 공유 액세스 기준
The results of the IPD will be published in a peer-reviewed journal.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ANALYTIC_CODE
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .